Samenvatting
Aims: The main aim is to identify Cognitive, Energetic, Behavioural and Affective (CEBA) profiles in Multiple Sclerosis (MS). When CEBA profiles have been determined, the next step is to develop a feasible screening tool used to match people with MS (pwMS) with a specific CEBA profile to existing neuropsychological treatment.
Method: The MS-CEBA study is an observational, prospective, multicenter cohort study consisting of three phases. Phase 1 focuses on identification of CEBA profiles in a large sample of pwMS (n=300). Phase 2 focuses on validating these CEBA profiles through replication of results in a new sample (n=100). After CEBA profiles have been determined, Phase 3 focuses on developing a feasible screening tool which combines CEBA profile with subjective burden in order to select from available neuropsychological treatment options. Primary outcome measure is CEBA status, determined through neuropsychological assessment consisting of tests and questionnaires regarding the CEBA domains. Subjective burden will be assessed using a structured interview. Inclusion criteria include MS diagnosis, sufficient ability in the Dutch language, and age 18-70.
Results: The study was launched in January 2023. Recruitment will start mid-2023 and continue until the end of 2026. Identification of multiple CEBA profiles is expected, from which a maximum of four will be selected. It is considered likely that multiple CEBA symptoms will be prominent within CEBA profiles, in which subjective burden will be used to help select from neuropsychological treatment options.
Discussion/conclusions: The MS-CEBA study is the first large scale study to investigate over the whole range of CEBA symptoms whether and how symptoms cluster, and thus if profiles can be identified. If so, a feasible screening tool allowing quick identification of CEBA profiles among pwMS will contribute to timely matching pwMS with specific CEBA profiles to suitable, existing neuropsychological treatment. This will improve societal participation among pwMS.
Method: The MS-CEBA study is an observational, prospective, multicenter cohort study consisting of three phases. Phase 1 focuses on identification of CEBA profiles in a large sample of pwMS (n=300). Phase 2 focuses on validating these CEBA profiles through replication of results in a new sample (n=100). After CEBA profiles have been determined, Phase 3 focuses on developing a feasible screening tool which combines CEBA profile with subjective burden in order to select from available neuropsychological treatment options. Primary outcome measure is CEBA status, determined through neuropsychological assessment consisting of tests and questionnaires regarding the CEBA domains. Subjective burden will be assessed using a structured interview. Inclusion criteria include MS diagnosis, sufficient ability in the Dutch language, and age 18-70.
Results: The study was launched in January 2023. Recruitment will start mid-2023 and continue until the end of 2026. Identification of multiple CEBA profiles is expected, from which a maximum of four will be selected. It is considered likely that multiple CEBA symptoms will be prominent within CEBA profiles, in which subjective burden will be used to help select from neuropsychological treatment options.
Discussion/conclusions: The MS-CEBA study is the first large scale study to investigate over the whole range of CEBA symptoms whether and how symptoms cluster, and thus if profiles can be identified. If so, a feasible screening tool allowing quick identification of CEBA profiles among pwMS will contribute to timely matching pwMS with specific CEBA profiles to suitable, existing neuropsychological treatment. This will improve societal participation among pwMS.
| Originele taal-2 | English |
|---|---|
| Status | Published - 2023 |
| Evenement | 8th Scientific Meeting of the Federation of the European Societies of Neuropsychology - Greece, Thessaloniki, Greece Duur: 27-sep.-2023 → 29-sep.-2023 Congresnummer: 8 |
Conference
| Conference | 8th Scientific Meeting of the Federation of the European Societies of Neuropsychology |
|---|---|
| Verkorte titel | FESN |
| Land/Regio | Greece |
| Stad | Thessaloniki |
| Periode | 27/09/2023 → 29/09/2023 |